Spinraza 12mg/5ml Injection is a groundbreaking pharmaceutical therapy containing nusinersen, used for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. This advanced medication works by increasing the production of survival motor neuron (SMN) protein, essential for maintaining healthy motor neurons, thereby improving muscle function and slowing disease progression.

Spinraza works by targeting the underlying genetic cause of SMA, modifying the splicing of the SMN2 gene to produce functional SMN protein. The injection is administered intrathecally under strict medical supervision, typically by trained healthcare professionals, ensuring safe and precise dosing. Treatment is given in scheduled loading and maintenance doses to achieve optimal therapeutic outcomes.

Spinraza 12 mg/5 ml injection provides hope for patients and families affected by this progressive neuromuscular disease. With consistent administration under specialist care, it helps improve motor function, enhances mobility, and supports a better quality of life. Spinraza is widely recognized in clinical practice for its efficacy and safety in managing SMA.

Product Features

• Contains Nusinersen 12 mg/5 ml
• Specifically treats Spinal Muscular Atrophy (SMA)
• Intrathecal administration under specialist supervision
• Increases survival motor neuron (SMN) protein production
• Improves motor function and slows disease progression

How It Helps

• Enhances motor neuron function
• Improves mobility and muscle strength
• Slows the progression of SMA
• Supports the overall quality of life in SMA patients